secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2022-05-17T23:59:59+00:00
Accession:  0001193125-22-152426
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVROBIO reports positive Phase 1/2 gene therapy data for cystinosis; all 5 patients off oral cysteamine
--------------------------------------------------------------------------------

- All five dosed patients remain off oral cysteamine post gene therapy; no drug-related adverse events reported.
- Early data show stabilization/improvement in visual motor integration, perception, and motor coordination scores (Beery VMI).
- Cystine crystals reduced in skin (8-81%) and intestinal mucosa (28-83%) across patients 1-3 post gene therapy.
- Photophobia scores improved or stable; patients #1,3,4,5 off cysteamine eye drops.
- AVROBIO-sponsored trial planned to begin in 2023 after regulatory interactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000119312522152426/0001193125-22-152426-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000119312522152426/d312223d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-152426

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer